Aligos Therapeutics Statistics
Total Valuation
ALGS has a market cap or net worth of $42.52 million. The enterprise value is -$50.51 million.
Important Dates
The next estimated earnings date is Monday, March 9, 2026, before market open.
| Earnings Date | Mar 9, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ALGS has 6.15 million shares outstanding. The number of shares has increased by 48.60% in one year.
| Current Share Class | 5.35M |
| Shares Outstanding | 6.15M |
| Shares Change (YoY) | +48.60% |
| Shares Change (QoQ) | +0.18% |
| Owned by Insiders (%) | 1.85% |
| Owned by Institutions (%) | 25.89% |
| Float | 3.14M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 23.13 |
| Forward PS | 23.16 |
| PB Ratio | 0.59 |
| P/TBV Ratio | 0.59 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.70, with a Debt / Equity ratio of 0.08.
| Current Ratio | 4.70 |
| Quick Ratio | 4.51 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -141.82% and return on invested capital (ROIC) is -79.06%.
| Return on Equity (ROE) | -141.82% |
| Return on Assets (ROA) | -54.70% |
| Return on Invested Capital (ROIC) | -79.06% |
| Return on Capital Employed (ROCE) | -98.81% |
| Weighted Average Cost of Capital (WACC) | 16.53% |
| Revenue Per Employee | $37,800 |
| Profits Per Employee | -$1.24M |
| Employee Count | 70 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, ALGS has paid $311,000 in taxes.
| Income Tax | 311,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -67.11% in the last 52 weeks. The beta is 2.66, so ALGS's price volatility has been higher than the market average.
| Beta (5Y) | 2.66 |
| 52-Week Price Change | -67.11% |
| 50-Day Moving Average | 9.14 |
| 200-Day Moving Average | 8.49 |
| Relative Strength Index (RSI) | 38.51 |
| Average Volume (20 Days) | 69,602 |
Short Selling Information
The latest short interest is 293,582, so 4.77% of the outstanding shares have been sold short.
| Short Interest | 293,582 |
| Short Previous Month | 268,943 |
| Short % of Shares Out | 4.77% |
| Short % of Float | 9.35% |
| Short Ratio (days to cover) | 3.77 |
Income Statement
In the last 12 months, ALGS had revenue of $2.65 million and -$86.46 million in losses. Loss per share was -$9.76.
| Revenue | 2.65M |
| Gross Profit | -65.80M |
| Operating Income | -86.73M |
| Pretax Income | -86.15M |
| Net Income | -86.46M |
| EBITDA | -85.82M |
| EBIT | -86.73M |
| Loss Per Share | -$9.76 |
Full Income StatementBalance Sheet
The company has $99.10 million in cash and $6.07 million in debt, with a net cash position of $93.03 million or $15.12 per share.
| Cash & Cash Equivalents | 99.10M |
| Total Debt | 6.07M |
| Net Cash | 93.03M |
| Net Cash Per Share | $15.12 |
| Equity (Book Value) | 71.83M |
| Book Value Per Share | 11.67 |
| Working Capital | 81.45M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$79.16 million and capital expenditures -$373,000, giving a free cash flow of -$79.53 million.
| Operating Cash Flow | -79.16M |
| Capital Expenditures | -373,000 |
| Free Cash Flow | -79.53M |
| FCF Per Share | -$12.92 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -3,277.93% |
| Pretax Margin | -3,255.90% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ALGS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -48.60% |
| Shareholder Yield | -48.60% |
| Earnings Yield | -203.34% |
| FCF Yield | -187.05% |
Analyst Forecast
The average price target for ALGS is $46.67, which is 575.40% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $46.67 |
| Price Target Difference | 575.40% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 110.33% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on August 19, 2024. It was a reverse split with a ratio of 1:25.
| Last Split Date | Aug 19, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:25 |
Scores
ALGS has an Altman Z-Score of -8.64 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -8.64 |
| Piotroski F-Score | 2 |
